ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients
暂无分享,去创建一个
Carl J Pepine | Joseph S Alpert | Robert M Califf | Gabriel Gregoratos | John W Beasley | Valentin Fuster | J. W. Schaeffer | R. Califf | E. Antman | J. Alpert | R. Gibbons | E. Braunwald | Sidney C. Smith | A. Jacobs | D. Faxon | G. Gregoratos | L. Hiratzka | V. Fuster | M. Cheitlin | J. Kupersmith | J. Hochman | C. Pepine | J. Beasley | P. Théroux | D. Kereiakes | D. Steward | T. Levin | Robert H. Jones | Earl E. Smith | Elliott M Antman | Sidney C Smith | David P Faxon | Raymond J Gibbons | Loren F Hiratzka | Alice K Jacobs | Eugene Braunwald | Joel Kupersmith | Judith S Hochman | Pierre Theroux | Robert H Jones | Melvin D Cheitlin | Dean Kereiakes | Thomas N Levin | John W Schaeffer | Earl E Smith | David E Steward | P. Théroux | Robert H. Jones | E. E. Smith | A. Jacobs
[1] Hugo A. Katus,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.
[2] M. Simoons. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial , 2001, The Lancet.
[3] The Esprit investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial , 2000, The Lancet.
[4] H. Schultheiss,et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). , 2000, The American journal of cardiology.
[5] A. Gawlinski,et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.
[6] Salim Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.
[7] J. W. Schaeffer,et al. ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .
[8] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[9] C. Grines,et al. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. , 2000, The Journal of invasive cardiology.
[10] N. Kleiman,et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. , 2001, American heart journal.
[11] E W Steyerberg,et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. , 2000, Circulation.
[12] L. Wallentin,et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial , 2000, The Lancet.
[13] B. Horne,et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. , 2001, The American journal of cardiology.
[14] V. Hasselblad,et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. , 2001, JAMA.
[15] E. Braunwald. Unstable angina : diagnosis and management , 1994 .
[16] C. Cannon,et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. , 1995, Journal of the American College of Cardiology.
[17] Graves Ej,et al. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1994. , 1997, Vital and health statistics. Series 13, Data from the National Health Survey.
[18] J. Eisenberg. Agency for Health Care Policy and Research. , 1999, Medical care.
[19] E. Braunwald,et al. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. , 2002, JAMA.
[20] E. Antman,et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. , 2002, European heart journal.
[21] R. Califf,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .
[22] C. Vassanelli,et al. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[23] C. Grines,et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. , 2001, The Journal of invasive cardiology.
[24] Richard P. Lewis,et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.
[25] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[26] R. Califf,et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.
[27] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[28] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.
[29] E. Topol,et al. Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up , 2002, Circulation.
[30] E. Braunwald,et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.
[31] G. Fonarow,et al. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. , 2001, Circulation.
[32] Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.
[33] V. Fuster,et al. Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[34] E. Topol,et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.
[35] C. Thalamas,et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. , 2000, Circulation.
[36] L. Wallentin,et al. Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.
[37] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[38] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[39] P. Nourjah. National Hospital Ambulatory Medical Care Survey: 1997 emergency department summary. , 1999 .
[40] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[41] G. Montalescot,et al. Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris , 2001, Circulation.